Working… Menu

Efficacy of Loteprednol Ointment Following Eyelid Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01749241
Recruitment Status : Withdrawn (no participant enrolled)
First Posted : December 13, 2012
Last Update Posted : August 2, 2019
Shiley Eye Center
Bausch & Lomb Incorporated
Information provided by (Responsible Party):
Bobby Korn, MD, PhD, University of California, San Diego

Brief Summary:
Inflammation occurs after any type of incisional surgery. This study will evaluate the efficacy of Loteprednol etabonate ointment vs. Soothe ointment (vehicle) for postoperative inflammation after routine eyelid surgery.

Condition or disease Intervention/treatment Phase
Post-operative Healing Following Blepharoplasty and Ptosis Repair Drug: Loteprednol etabonate ophthalmic ointment Drug: Vehicle Ophthalmic Ointment Not Applicable

Detailed Description:
Eyelid surgery such as blepharoplasty is often performed for functional and cosmetic indications. Following any incisional surgery, postoperative inflammation occurs at the surgical site. This study will evaluate the efficacy of reducing postoperative inflammation after bilateral eyelid surgery using Loteprednol etabonate (steroid) vs. Soothe ointment (vehicle of Loteprednol etabonate). Common postoperative changes at the incision include: erythema, thickening/elevation of the skin, pigmentary changes and pain. The use of a topically applied steroid would be expected to reduce inflammation and this study will evaluate this. For each patient, one eyelid will be randomly chosen to treat with medication and the other eyelid will be treated with vehicle ointment and by using the same patient, each patient will be internally controlled. Antibiotic prophylaxis is often given after eyelid surgery and this will be used in all patients in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Loteprednol Etabonate Ophthalmic Ointment vs. Soothe Night Time Ointment for Inflammation Following Eyelid Surgery
Study Start Date : September 2012
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Loteprednol etabonate ointment
This is the arm which contains loteprednol steroid
Drug: Loteprednol etabonate ophthalmic ointment
Thin ribbon ointment to assigned eye twice daily for 14 days
Other Name: Lotemax ophthalmic ointment

Vehicle Ointment
This arm contains vehicle only.
Drug: Vehicle Ophthalmic Ointment
Thin ribbon ointment to assigned eye twice daily for 14 days

Primary Outcome Measures :
  1. Inflammation [ Time Frame: 24 weeks after surgery ]
    Inflammatory changes of the periocular skin will be assessed by several criteria including: 1. Erythema 2. Wound elevation 3. Pigmentary changes 4. Exudate 5. Excoriation 6. Crusting 7. Scaling 8. Pain 9. Itching

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age > 18 years old
  • Scheduled for bilateral eyelid surgery
  • Willing and able to return for all study visits
  • Willing and able to administer treatments as required
  • Understand and sign informed consent approved by UCSD institutional review board

Exclusion Criteria:

  • History of allergy to investigational drug (Loteprednol etabonate) or ingredient in drug including petrolatum
  • History of collagen vascular disease and receiving concurrent treatment that could interfere with interpretation of study results
  • Concurrent ocular therapy with nonsteroidal anti-inflammatory drugs, mast cell stabilizers, antihistamines, decongestants, immunosuppresants, and systemic or ocular corticosteroids
  • History of immunodeficiency
  • Prior eyelid or facial surgery
  • Prior ocular or orbital trauma
  • History of ocular hypertension, steroid responder, or glaucoma
  • Pregnancy or lactation
  • Uncontrolled systemic disease or significant illness
  • Any other condition the investigator believe would pose a significant hazard to the subject if the investigational therapy were initiated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01749241

Layout table for location information
United States, California
Shiley Eye Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Shiley Eye Center
Bausch & Lomb Incorporated
Layout table for investigator information
Principal Investigator: Bobby Korn, MD PhD UCSD Med
Publications of Results:
Layout table for additonal information
Responsible Party: Bobby Korn, MD, PhD, Associate Professor of Ophthalmology, University of California, San Diego Identifier: NCT01749241    
Other Study ID Numbers: BL31929
First Posted: December 13, 2012    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Loteprednol Etabonate
Anti-Allergic Agents